Change of Adviser

Oxford Biomedica PLC
25 November 2002

25 November 2002



For further information, please contact:


Oxford BioMedica plc
Professor Alan Kingsman - Chief Executive             Tel:  [phone]

Collins Stewart Limited
Jonathan Kwok                                               Tel: [phone]

City/Financial Enquiries - Beattie Financial
Mike Wort, James Chandler                                   Tel: [phone]

Scientific / Trade Press Enquiries - Charles Consultants
Sue Charles, Katja Stout                                    Tel: [phone]







   OXFORD BIOMEDICA PLC APPOINTS COLLINS STEWART LIMITED AS CORPORATE BROKER


Oxford, United Kingdom

25 November 2002


Oxford BioMedica plc announces today that it has appointed Collins Stewart
Limited as its Corporate Broker.  This appointment takes effect immediately.



                                     -Ends-



Notes to Editors


1.      Oxford BioMedica plc


Established in 1995 as a spin out from Oxford University, Oxford BioMedica is an
international biotechnology company with a diverse portfolio of products and
technology, specialising in gene-based products and technology in the areas of
cancer, neurological disease, cardiovascular disease and blood disorders. This
is underpinned by over 70 patent families, about quarter of which are issued.
Oxford BioMedica plc was floated on the Alternative Investment Market of the
London Stock Exchange in December 1996, and was promoted to the United Kingdom
Listing Authority Official List in April 2001 following a successful £35.5
million fund-raising.

Oxford BioMedica is headquartered in Oxford, UK and has a wholly-owned
subsidiary in San Diego, USA

Currently Oxford BioMedica has corporate collaborations with Aventis, IDM,
Amersham, Valentis, Virbac and Wyeth. BioMedica has two products in Phase I/II
clinical trials: MetXia(R) for late-stage breast cancer, and TroVax(R) for
late-stage colorectal cancer.



2.      World Wide Web

Further information is available on the World Wide Web at http://
www.oxfordbiomedica.co.uk.





                      This information is provided by RNS
            The company news service from the London Stock Exchange